
CLINIGEN GROUP PLC LS-001
Share · GB00B89J2419 · A1J440 (XLON)
No Price
n/a
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
- | - | - | - | - | - | - |
Company Profile for CLINIGEN GROUP PLC LS-001 Share
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Invested Funds
The following funds have invested in: CLINIGEN GROUP PLC LS-001 invested:
Fund | Vol. in million 1.081,40 | Percentage (%) 0,18 % |
Company Data
Name CLINIGEN GROUP PLC LS-001
Company Clinigen Group plc
Website
https://www.clinigengroup.com
Primary Exchange
London

WKN A1J440
ISIN GB00B89J2419
Asset Class Share
Sector Healthcare
Industry Medical - Distribution
CEO Mr. Shaun Chilton
Country United Kingdom
Currency GBP
Employees 1,0 T
Address Pitcairn House, Crown Square, First Avenue, DE14 2WW STAFFORDSHIRE
IPO Date 2012-09-25
Dividends from 'CLINIGEN GROUP PLC LS-001'
Ex-Date | Dividend per Share |
---|---|
02.12.2021 | 5,46 GBX |
18.03.2021 | 2,15 GBX |
05.11.2020 | 5,46 GBX |
19.03.2020 | 2,15 GBX |
07.11.2019 | 4,75 GBX |
21.03.2019 | 1,95 GBX |
08.11.2018 | 3,84 GBX |
22.03.2018 | 1,76 GBX |
09.11.2017 | 3,40 GBX |
23.03.2017 | 1,60 GBX |
Ticker Symbols
Name | Symbol |
---|---|
London | CLIN.L |
More Shares
Investors who CLINIGEN GROUP PLC LS-001 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.